Literature DB >> 33348663

Effect of Body Weight and Other Metabolic Factors on Risk of Non-Small Cell Lung Cancer among Veterans with HIV and a History of Smoking.

Jose M Garcia1,2, Jennifer R Kramer3,4,5,6, Peter A Richardson3,6, Sarah Ahmed3,6, Kathryn E Royse3, Donna L White3,4,5,6, Suchismita Raychaudhury3,6, Elaine Chang3, Christine M Hartman3,6, Michael J Silverberg7, Elizabeth Y Chiao3,4,5,6.   

Abstract

Among people living with HIV (PWH), there has been an increasing incidence of non-small cell lung cancer (NSCLC) and metabolic abnormalities, including dyslipidemia, which can modulate NSCLC risk. In this article, we evaluate which metabolic risk factors are associated with incident risk among PWH who smoke. This is done through a retrospective cohort study, using data of HIV+ veterans who smoke from the nationwide Veterans Affairs (VA) healthcare system. Data on diagnostic codes, medication, and laboratory values of 33,351 veterans were obtained using the VA's Corporate Data Warehouse and Central Cancer Registry. We calculated NSCLC incidence and utilized Cox regression to determine metabolic factors associated with NSCLC risk. HIV+ cohort was 97.4% male; median age = 47 years and 20,050 (60.1%) well-controlled (≥80% follow-up time undetectable viral load). Crude incidence rates were lower in well-controlled PWH (1.46 vs. 2.06/1000 PY). Metabolic factors associated with incident NSCLC risk included lower BMI at HIV diagnosis and cachexia history in both groups, while HDL and triglycerides were significant in non-well-controlled smokers only. Our findings that lower BMI at HIV diagnosis, history of cachexia among individuals with well-controlled HIV, and cachexia presence at diagnosis are associated with increased risk of developing NSCLC in PWH with a history of smoking have important implications.

Entities:  

Keywords:  AIDS; antiretroviral therapy; cachexia; lung cancer; statins

Year:  2020        PMID: 33348663      PMCID: PMC7765814          DOI: 10.3390/cancers12123809

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.575


  28 in total

1.  Lipodystrophy and dyslipidemia among patients taking first-line, World Health Organization-recommended highly active antiretroviral therapy regimens in Western India.

Authors:  Sanjay N Pujari; Ameet Dravid; Eknath Naik; Shobha Bhagat; Kaley Tash; Jeffrey P Nadler; John T Sinnott
Journal:  J Acquir Immune Defic Syndr       Date:  2005-06-01       Impact factor: 3.731

2.  Body mass index and risk of lung cancer among never, former, and current smokers.

Authors:  Llewellyn Smith; Louise A Brinton; Margaret R Spitz; Tram Kim Lam; Yikyung Park; Albert R Hollenbeck; Neal D Freedman; Gretchen L Gierach
Journal:  J Natl Cancer Inst       Date:  2012-03-27       Impact factor: 13.506

3.  Total cholesterol and cancer risk in a large prospective study in Korea.

Authors:  Cari M Kitahara; Amy Berrington de González; Neal D Freedman; Rachel Huxley; Yejin Mok; Sun Ha Jee; Jonathan M Samet
Journal:  J Clin Oncol       Date:  2011-03-21       Impact factor: 44.544

4.  Patterns of the hazard of death after AIDS through the evolution of antiretroviral therapy: 1984-2004.

Authors:  Michael F Schneider; Stephen J Gange; Carolyn M Williams; Kathryn Anastos; Ruth M Greenblatt; Lawrence Kingsley; Roger Detels; Alvaro Muñoz
Journal:  AIDS       Date:  2005-11-18       Impact factor: 4.177

5.  Quality of nonmetastatic colorectal cancer care in the Department of Veterans Affairs.

Authors:  George L Jackson; L Douglas Melton; David H Abbott; Leah L Zullig; Diana L Ordin; Steven C Grambow; Natia S Hamilton; S Yousuf Zafar; Ziad F Gellad; Michael J Kelley; Dawn Provenzale
Journal:  J Clin Oncol       Date:  2010-06-01       Impact factor: 44.544

6.  Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease.

Authors:  Fasiha Kanwal; Jennifer R Kramer; Srikar Mapakshi; Yamini Natarajan; Maneerat Chayanupatkul; Peter A Richardson; Liang Li; Roxanne Desiderio; Aaron P Thrift; Steven M Asch; Jinna Chu; Hashem B El-Serag
Journal:  Gastroenterology       Date:  2018-08-23       Impact factor: 22.682

7.  Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles?

Authors:  E Fontas; F van Leth; C A Sabin; N Friis-Møller; M Rickenbach; A d'Arminio Monforte; O Kirk; M Dupon; L Morfeldt; S Mateu; K Petoumenos; W El-Sadr; S de Wit; J D Lundgren; C Pradier; P Reiss
Journal:  J Infect Dis       Date:  2004-03-02       Impact factor: 5.226

8.  HIV and HAART-Associated Dyslipidemia.

Authors:  Eoin R Feeney; Patrick W G Mallon
Journal:  Open Cardiovasc Med J       Date:  2011-02-24

9.  HIV Infection and Circulating Levels of Prosurfactant Protein B and Surfactant Protein D.

Authors:  Meredith S Shiels; Gregory D Kirk; M Bradley Drummond; Dilsher Dhillon; Samir M Hanash; Ayumu Taguchi; Eric A Engels
Journal:  J Infect Dis       Date:  2018-01-17       Impact factor: 7.759

10.  Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study.

Authors:  Stephane De Wit; Caroline A Sabin; Rainer Weber; Signe Westring Worm; Peter Reiss; Charles Cazanave; Wafaa El-Sadr; Antonella d'Arminio Monforte; Eric Fontas; Matthew G Law; Nina Friis-Møller; Andrew Phillips
Journal:  Diabetes Care       Date:  2008-02-11       Impact factor: 17.152

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.